| Quarterly Financials | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 463 | 457 | 532 | 472 | 486 | 459 | 441 | 450 | 508 | 558 | 463 | 543 | 562 | 388 |
| Expenses | 385 | 371 | 441 | 385 | 405 | 374 | 352 | 353 | 388 | 459 | 364 | 409 | 418 | 293 |
| EBITDA | 78 | 86 | 91 | 87 | 81 | 85 | 89 | 97 | 120 | 99 | 98 | 134 | 144 | 95 |
| Operating Profit % | 16 % | 19 % | 17 % | 18 % | 16 % | 19 % | 20 % | 21 % | 23 % | 17 % | 20 % | 24 % | 26 % | 24 % |
| Depreciation | 14 | 14 | 17 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 21 | 23 | 23 | 23 |
| Interest | 5 | 4 | 6 | 5 | 6 | 4 | 4 | 5 | 5 | 5 | 6 | 10 | 7 | 7 |
| Profit Before Tax | 60 | 68 | 69 | 65 | 59 | 64 | 67 | 74 | 96 | 74 | 72 | 101 | 115 | 65 |
| Tax | 11 | 16 | 18 | 17 | 16 | 17 | 15 | 21 | 31 | 18 | 17 | 27 | 26 | 16 |
| Net Profit | 49 | 52 | 51 | 48 | 43 | 47 | 52 | 53 | 65 | 56 | 55 | 74 | 88 | 50 |
| EPS in ₹ | 5.39 | 5.72 | 5.64 | 5.26 | 4.73 | 5.20 | 5.72 | 5.82 | 7.20 | 6.12 | 6.03 | 8.16 | 9.75 | 5.46 |
Aarti Pharma Labs
Aarti Pharma Labs
843.90
-0.70
(-0.08%)
Key Fundamentals
Market Cap
7,655.60 Cr
EPS
30.06
PE Ratio
28.73
Dividend Yield
0.59 %
Industry
Healthcare 52 Week High
971.00
52 Week Low
557.05
PB Ratio
3.85
Debt to Equity
0.19
Sector
Pharmaceuticals Actual
Company News
View All News
Aarti Pharmalabs Schedules Earnings Conference Call for Q2-FY26 Results1 day ago
Aarti Pharmalabs Limited has scheduled an earnings conference call for investors and analysts on Tuesday, November 11, 2025, at 4:00 PM IST to discuss the company's Q2-FY26 financial results. The call will feature Chairman Rashesh Gogri, Vice Chairperson and Managing Director Hetal Gogri Gala, and Chief Financial Officer Piyush Lakhani. The company has provided multiple dial-in numbers for domestic and international participants across various countries. The conference call is being organized by Emkay Global Financial Services Ltd.
Delhi High Court Issues Injunction Against Aarti Pharma Labs Over Ruxolitinib Patent DisputeOct 08, 2025
The Delhi High Court has issued an ex-parte ad-interim injunction against Aarti Pharma Labs Ltd, stopping the company from manufacturing and supplying Ruxolitinib products due to a patent infringement claim. The company states that this injunction will not impact its overall operations.
Aarti Pharmalabs Sets Record Date for ₹2.5 Final Dividend PaymentAug 19, 2025
Aarti Pharmalabs Limited has established September 15, 2025 as the record date for final dividend payment of ₹2.5 per equity share for financial year 2024-25. The dividend represents 50% of the face value of ₹5 per share and requires shareholder approval at the Annual General Meeting scheduled for September 22, 2025. Payment will be made to shareholders whose names appear in the company's register on the record date, with distribution expected on or before October 20, 2025.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,685.90 | #1 4,05,487.60 | 39.07 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 54.39 | |
6,883.50 | 1,80,638.10 | 78.26 | 9,712.00 | 18.67 | 2,191 | 26.74 | 74.24 | |
1,501.50 | 1,21,429.70 | 22.35 | 28,409.50 | 7.12 | 5,291 | 3.71 | 39.79 | |
3,553.40 | 1,20,994.20 | 60.46 | 11,539.40 | 6.99 | 1,911 | 19.91 | 46.89 | |
1,205.20 | 1,00,153.70 | #1 17.47 | 33,741.20 | 16.73 | 5,725 | -0.38 | 36.98 | |
2,309.10 | 97,803.10 | 51.13 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 28.96 | |
936.70 | 97,775.80 | 20.78 | 23,511.00 | 18.55 | 4,615 | 34.60 | 30.29 | |
1,955.50 | 89,318.30 | 24.52 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 50.08 | |
5,643.50 | 67,721.60 | 29.03 | 13,458.30 | 3.70 | 2,216 | 21.39 | 62.15 | |
1,140.60 | 66,739.90 | 19.90 | 32,345.60 | 9.43 | 3,484 | 3.81 | 59.80 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
14.41 %
Net Income Growth
25.59 %
Cash Flow Change
53.25 %
ROE
10.94 %
ROCE
2.38 %
EBITDA Margin (Avg.)
6.08 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 0 | 2,040 | 2,244 | 2,582 | 2,906 |
| Fixed Assets | 0 | 782 | 926 | 1,033 | 1,137 |
| Current Assets | 0 | 1,028 | 1,163 | 1,346 | 1,322 |
| Capital Work in Progress | 0 | 187 | 102 | 137 | 374 |
| Investments | 0 | 32 | 87 | 107 | 77 |
| Other Assets | 0 | 1,038 | 1,130 | 1,305 | 1,319 |
| Total Liabilities | 0 | 2,040 | 2,244 | 2,582 | 2,906 |
| Current Liabilities | 0 | 581 | 601 | 694 | 657 |
| Non Current Liabilities | 0 | 73 | 85 | 131 | 259 |
| Total Equity | 0 | 1,387 | 1,559 | 1,757 | 1,990 |
| Reserve & Surplus | 0 | 1,341 | 1,513 | 1,712 | 1,945 |
| Share Capital | 0 | 0 | 45 | 45 | 45 |
Cash Flow
| Cash Flow | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 78 | -71 | 12 | -17 |
| Investing Activities | 0 | -139 | -158 | -215 | -414 |
| Operating Activities | 0 | -44 | 250 | 216 | 332 |
| Financing Activities | 0 | 260 | -164 | 10 | 65 |
Share Holding
| % Holding | Jan 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 44.16 % | 45.98 % | 45.98 % | 46.30 % | 46.46 % | 46.46 % | 46.46 % | 46.10 % | 44.66 % | 44.29 % | 43.72 % | 42.88 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 8.16 % | 8.32 % | 7.06 % | 7.38 % | 8.64 % | 7.36 % | 7.35 % | 8.02 % |
| DIIs | 14.73 % | 13.70 % | 10.66 % | 10.51 % | 9.91 % | 9.97 % | 11.47 % | 11.35 % | 10.36 % | 7.53 % | 7.80 % | 6.96 % |
| Government | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 24.66 % | 28.35 % | 30.23 % | 29.13 % | 29.74 % | 29.71 % | 29.57 % | 29.45 % | 30.39 % | 34.10 % | 34.43 % | 35.39 % |
| Others | 16.44 % | 11.96 % | 13.12 % | 14.04 % | 5.72 % | 5.52 % | 5.43 % | 5.71 % | 5.94 % | 6.71 % | 6.69 % | 6.74 % |
| No of Share Holders | 3,05,456 | 2,76,664 | 2,58,236 | 2,26,286 | 2,15,796 | 2,04,122 | 1,89,012 | 1,85,436 | 1,85,111 | 1,96,314 | 1,87,039 | 1,90,655 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2 | 3 | 5 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.46 | 0.4 | 0.59 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 09 Nov 2025 |  Quarterly Result Announcement | NA | 09 Nov 2025 | 832.20 | 844.60 |
| 19 Feb 2024 |  Dividend | ₹ 2.00 /share | 16 Feb 2024 | 550.70 | 536.20 |
| 31 Jul 2024 | Dividend | ₹ 1.00 /share | 31 Jul 2024 | 502.45 | 614.95 |
| 07 Aug 2024 |  Annual General Meeting | NA | 07 Aug 2024 | 608.50 | 595.85 |
| 28 Oct 2024 | Quarterly Result Announcement | NA | 28 Oct 2024 | 610.40 | 605.40 |
| 05 Feb 2025 | Quarterly Result Announcement | NA | 05 Feb 2025 | 599.00 | 623.00 |
| 14 Feb 2025 | Dividend | ₹ 2.50 /share | 14 Feb 2025 | 623.00 | 733.45 |
| 10 May 2025 | Quarterly Result Announcement | NA | 10 May 2025 | 754.25 | 767.35 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 911.20 | 857.15 |
| 15 Sept 2025 | Dividend | ₹ 2.50 /share | 15 Sept 2025 | 767.35 | 926.55 |
| 22 Sept 2025 | Annual General Meeting | NA | 22 Sept 2025 | 845.95 | 930.20 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2 days ago
2 days agoBoard Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Standalone And Consolidated Financial Results For The Second Quarter And Half Year Ended September 30 202510 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 13, 2025
Oct 13, 2025Ex-Parte Ad-Interim Injunction Order Regarding Pharmaceutical Drug Product Containing Ruxolitinib And/Or Ruxolitinib Phosphate APIOct 08, 2025
Oct 08, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Oct 07, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationSep 23, 2025
Sep 23, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 23, 2025
Sep 23, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 23, 2025
Sep 23, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 22, 2025
Sep 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 30, 2025
Aug 30, 2025Reg. 34 (1) Annual Report.Aug 29, 2025
Aug 29, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 29, 2025
Aug 29, 2025Notice Of 6Th Annual General MeetingAug 29, 2025
Aug 29, 2025Intimation Regarding 100 Days Campaign - Saksham NiveshakAug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 20, 2025
Aug 20, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 20, 2025
Aug 20, 2025Record Date For Final Dividend For FY 2024-25Aug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 12, 2025
Aug 12, 2025Financial Results For Quarter Ended June 30 2025Aug 12, 2025
Aug 12, 2025Appointment Of Secretarial AuditorAug 12, 2025
Aug 12, 2025Board Meeting Outcome for Outcome Of Board Meeting For Approval Of Unaudited Financial Results With Limited Review Report For The Quarter Ended June 30 2025Aug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Aug 05, 2025Board Meeting Intimation for Board Meeting Intimation For Unaudited Financial Results For The Quarter Ended June 30 2025.Aug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Credit RatingJul 17, 2025
Jul 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Jul 09, 2025Closure of Trading WindowJun 25, 2025
Jun 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Jun 18, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 16, 2025
May 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 12, 2025
May 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 12, 2025
May 12, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 12, 2025
May 12, 2025Grant Of Options Under PSOP Scheme 2023May 10, 2025
May 10, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 10, 2025
May 10, 2025Results For The Financial Year Ended 31.03.2025May 10, 2025
May 10, 2025Board Meeting Outcome for Outcome Of The Board Meeting Dated 10 May 2025May 10, 2025
May 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 05, 2025
May 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 29, 2025
Apr 29, 2025Board Meeting Intimation for Audited Financial Results For The Year Ended March 31 2025 And Recommendation Of Dividend If Any For The Financial Year Ended March 31 2025.Apr 25, 2025
Apr 25, 2025Intimation Of Change In Email And Website Address Of Registrar And Share Transfer Agent (RTA)Apr 18, 2025
Apr 18, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 16, 2025
Apr 16, 2025Mutual Fund Holdings
HDFC Multi Cap Fund Direct - Growth 
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth 
Unifi Flexi Cap Fund Direct-Growth 
Groww Nifty Total Market Index Fund Direct - Growth 
Bandhan BSE Healthcare Index Fund Direct-Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
Mirae Asset Nifty Total Market Index Fund Direct-Growth 
Quant Business Cycle Fund Direct-Growth 
Samco Active Momentum Fund Direct - Growth 
Union Active Momentum Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 49.79
ATR(14)
Less Volatile 22.14
STOCH(9,6)
Neutral 42.39
STOCH RSI(14)
Overbought 83.48
MACD(12,26)
Bullish 3.11
ADX(14)
Weak Trend 15.88
UO(9)
Bearish 47.71
ROC(12)
Downtrend And Accelerating -1.36
WillR(14)
Neutral -55.27
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
